糖尿病肾脏疾病肾性贫血认识与管理中国专家共识（2023年版）解读

摘要/Abstract

中图分类号:

R587.1
R692

王伟铭. 糖尿病肾脏疾病肾性贫血认识与管理中国专家共识（2023年版）解读[J]. 内科理论与实践, 2023, 18(03): 137-140.

WANG Weiming. Interpretation of Chinese expert consensus on understanding and management of renal anemia in diabetic kidney disease[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(03): 137-140.

参考文献36

[1]	Ito K, Yokota S, Watanabe M, et al. Anemia in diabetic patients reflects severe tubulointerstitial injury and aids in clinically predicting a diagnosis of diabetic nephropathy[J]. Intern Med, 2021, 60(9): 1349-1357. doi:10.2169/internalmedicine.5455-20 URL
[2]	Shams N, Osmani MH. Newly diagnosed anemia in admitted diabetics, frequency, etiology and associated factors[J]. J Coll Physicians Surg Pak, 2015, 25(4): 242-246.
[3]	Miulescu RD, Neamtu MC, Margină D, et al. Associations between thyroid dysfunction and chronic kidney disease[J]. Romanian Journal of Diabetes Nutrition and Metabolic Diseases, 2014, 21(1): 37-42. doi:10.2478/rjdnmd-2014-0006 URL
[4]	Basu G, Mohapatra A. Interactions between thyroid disorders and kidney disease[J]. Indian J Endocrinol Metab, 2012, 16(2): 204-213. doi:10.4103/2230-8210.93737pmid:22470856
[5]	Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994)[J]. Arch Intern Med, 2002, 162(12): 1401-1408. doi:10.1001/archinte.162.12.1401pmid:12076240
[6]	许惠婵, 张海红, 刘妙燕. 慢性肾小球肾病与糖尿病肾病维持血液透析患者的贫血对照研究[J]. 中国医药科学, 2012, 2(14): 197-199.
[7]	范秀芳, 王嘉佳, 刁建辉, 等. 糖尿病肾病与非糖尿病肾病贫血的对照研究[J]. 中国当代医药, 2015, 22(24): 35-37.
[8]	Camargo JL, Gross JL. Conditions associated with very low values of glycohaemoglobin measured by an HPLC method[J]. J Clin Pathol, 2004, 57(4): 346-349. doi:10.1136/jcp.2002.007088pmid:15047733
[9]	Kidney Disease: Improving Global Outcomes KDIGO Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease[J]. Kidney Int Suppl, 2012, 2(4):279-335. doi:10.1038/ki.1972.107 URL
[10]	Ghoti H, Rachmilewitz EA, Simon-Lopez R, et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron[J]. Eur J Haematol, 2012, 89(1): 87-93. doi:10.1111/j.1600-0609.2012.01783.xpmid:22435497
[11]	Ueda N, Takasawa K. Impact of inflammation on ferritin, hepcidin and the management of iron deficiency anemia in chronic kidney disease[J]. Nutrients, 2018, 10(9): 1173. doi:10.3390/nu10091173 URL
[12]	Loutradis C, Skodra A, Georgianos P, et al. Diabetes mellitus increases the prevalence of anemia in patients with chronic kidney disease: a nested case-control study[J]. World J Nephrol, 2016, 5(4): 358-366. doi:10.5527/wjn.v5.i4.358 URL
[13]	中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志, 2021, 101(20): 1463-1502.
[14]	Kim SH, Lee KA, Jin HY, et al. The relationship between anemia and the initiation of dialysis in patients with type 2 diabetic nephropathy[J]. Diabetes Metab J, 2015, 39(3): 240-246. doi:10.4093/dmj.2015.39.3.240pmid:26124994
[15]	Toft G, Heide-Jørgensen U, van Haalen H, et al. Anemia and clinical outcomes in patients with non-dialysis dependent or dialysis dependent severe chronic kidney disease: a Danish population-based study[J]. J Nephrol, 2020, 33(1): 147-156. doi:10.1007/s40620-019-00652-9pmid:31587136
[16]	O’Mara NB. Anemia in patients with chronic kidney disease[J]. Diabetes Spectr, 2008, 21(1): 12-19. doi:10.2337/diaspect.21.1.12 URL
[17]	Aso Y, Suganuma R, Wakabayashi S, et al. Anemia is associated with an elevated serum level of high-molecular-weight adiponectin in patients with type 2 diabetes independently of renal dysfunction[J]. Transl Res, 2009, 154(4):175-182. doi:10.1016/j.trsl.2009.07.005pmid:19766961
[18]	Tarng DC. Cardiorenal anemia syndrome in chronic kidney disease[J]. J Chin Med, 2007, 70(10):424-429.
[19]	Kliger AS, Foley RN, Goldfarb DS, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD[J]. Am J Kidney Dis, 2013, 62(5): 849-859. doi:10.1053/j.ajkd.2013.06.008pmid:23891356
[20]	KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease[J]. Am J Kidney Dis, 2007, 49(2 Suppl 2):S12-S154. doi:10.1053/j.ajkd.2006.12.005pmid:17276798
[21]	Mikhail A, Brown C, Williams JA, et al. Renal association clinical practice guideline on anaemia of chronic kidney disease[J]. BMC Nephrol, 2017, 18(1):345. doi:10.1186/s12882-017-0688-1pmid:29191165
[22]	National Institute for Health and Care Excellence. Chronic kidney disease: assessment and management[M/OL]. London: National Institute for Health and Care Excellence (NICE), 2021, https://www.nice.org.uk/guidance/ng203.
[23]	Panchapakesan U, Sumual S, Pollock C. Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator)[J]. Int J Nanomedicine, 2007, 2(1): 33-38. pmid:17722510
[24]	Mehdi U, Toto RD. Anemia, diabetes, and chronic kidney disease[J]. Diabetes Care, 2009, 32(7): 1320-1326. doi:10.2337/dc08-0779pmid:19564475
[25]	Koulouridis I, Alfayez M, Trikalinos TA, et al. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis[J]. Am J Kidney Dis, 2013, 61(1): 44-56. doi:10.1053/j.ajkd.2012.07.014pmid:22921639
[26]	Del Vecchio L, Longhi S, Locatelli F. Safety concerns about intravenous iron therapy in patients with chronic kidney disease[J]. Clin Kidney J, 2016, 9(2): 260-267. doi:10.1093/ckj/sfv142pmid:26985378
[27]	Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease[J]. N Engl J Med, 2009, 361(21): 2019-2032. doi:10.1056/NEJMoa0907845 URL
[28]	Ritz E, Laville M, Bilous RW, et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study[J]. Am J Kidney Dis, 2007, 49(2):194-207. doi:10.1053/j.ajkd.2006.11.032pmid:17261422
[29]	Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis[J]. N Engl J Med, 2019, 381(11): 1011-1022. doi:10.1056/NEJMoa1901713 URL
[30]	Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis[J]. N Engl J Med, 2019, 381(11): 1001-1010. doi:10.1056/NEJMoa1813599 URL
[31]	Zhang L, Liu Y, Huang Y, et al. Effect of roxadustatversuserythropoietin(EPO) for treating anemia in patients with diabetic kidney disease: a retrospective cohort study[J]. Ann Transl Med, 2022, 10(22): 1224. doi:10.21037/atm-22-4344pmid:36544686
[32]	中国研究型医院学会肾脏病学专业委员会. 罗沙司他治疗肾性贫血中国专家共识[J]. 中华医学杂志, 2022, 102(24): 1802-1810.
[33]	Minutolo R, Garofalo C, Chiodini P, et al. Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease[J]. Nephrol Dial Transplant, 2021, 36(2): 267-274. doi:10.1093/ndt/gfaa088 URL
[34]	Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD[J]. J Am Soc Nephrol, 2008, 19(8): 1599-605. doi:10.1681/ASN.2007101156pmid:18525001
[35]	Shukla R, Mishra N. Management of iron deficiency anemia-recent challenges[J]. Indian J Res, 2015, 4: 100-102.
[36]	中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组. 肾性贫血诊断与治疗中国专家共识(2018 修订版)[J]. 中华肾脏病杂志, 2018, 34(11): 860-866. doi:10.3760/cma.j.issn.1001-7097.2018.11.012

糖尿病肾脏疾病肾性贫血认识与管理中国专家共识（2023年版）解读

Interpretation of Chinese expert consensus on understanding and management of renal anemia in diabetic kidney disease

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献36

相关文章15

编辑推荐

Metrics

本文评价

[1]	毕礼明, 王朝晖.糖尿病肾病发病机制研究进展[J]. 内科理论与实践, 2023, 18(03): 201-205.
[2]	张小月, 王伟铭.盐皮质激素受体拮抗剂在糖尿病肾病治疗中的研究进展[J]. 内科理论与实践, 2023, 18(03): 206-210.
[3]	高玉莲, 冯耘, 倪磊.糖尿病人群中耐药革兰阴性菌血流感染的研究进展[J]. 内科理论与实践, 2023, 18(02): 124-127.
[4]	张梦潇, 韦晓, 张少红, 陈国芳, 刘超.生长分化因子15：减重治疗的新靶点[J]. 内科理论与实践, 2023, 18(02): 128-130.
[5]	中华医学会内分泌学分会.老年与儿童青少年糖尿病人群新型冠状病毒感染临床应对指南[J]. 内科理论与实践, 2023, 18(01): 10-12.
[6]	张梦潇, 孙烁烁, 韦晓, 张少红, 陈国芳, 刘超.生酮饮食诱导db/db小鼠肝脏脂肪沉积[J]. 内科理论与实践, 2023, 18(01): 56-63.
[7]	卜凡玉　郭晓峰　徐鹏　王进　薛明宇　潘筱云.抗生素骨水泥联合其他综合干预措施治疗糖尿病足骨髓炎[J]. 组织工程与重建外科杂志, 2022, 18(4): 328-.
[8]	缪雅, 刘丽丽, 侯田志超, 严青华, 庞怡, 吴春晓, 程旻娜, 施燕, 黎衍云, 田景琰.上海糖尿病前期人群恶性肿瘤发病风险分析[J]. 内科理论与实践, 2022, 17(06): 435-440.
[9]	阮铭, 侯田志超, 王海燕, 黎衍云, 周冰心, 包超慧, 秦洁洁, 王宇光, 方海, 朱伟嵘, 田景琰.糖尿病前期“治未病”的几何深度学习与计算医学研究展望[J]. 内科理论与实践, 2022, 17(06): 475-481.
[10]	秦雪, 郭华, 张云云, 崔小川.C1q肿瘤坏死因子相关蛋白3与代谢相关疾病的研究进展[J]. 内科理论与实践, 2022, 17(06): 482-485.
[11]	许晴, 邵慧英, 陈帅, 全进伟, 周清芬, 王敏慧.延续健康教育和指导对干预2型糖尿病患者冠状动脉斑块进展的影响[J]. 内科理论与实践, 2022, 17(04): 330-333.
[12]	高晶晶, 高艳虹.早发2型糖尿病流行病学、临床特征及病因机制的研究进展[J]. 内科理论与实践, 2022, 17(04): 344-348.
[13]	孙洪平, 陈国芳, 刘超.植物性饮食与2型糖尿病的研究进展[J]. 内科理论与实践, 2022, 17(04): 349-352.
[14]	中华医学会内分泌学分会.新型冠状病毒肺炎疫情下糖尿病管理专家建议[J]. 诊断学理论与实践, 2022, 21(02): 136-138.
[15]	陈煦阳, 顾卫琼.胰岛素自身抗体临床检测应用局限及对策研究进展[J]. 诊断学理论与实践, 2022, 21(01): 95-98.